Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (81-90 of 635) with videos related to

Pageof 64
Sort By:
Cardiovascular Diabetology|September 23, 2022
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failureSok Cin Tye, Niels Jongs, Steven G Coca, et al.
Circulation|March 19, 2019
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes MellitusGemma A Figtree, Karin Rådholm, Terrance D Barrett, et al.
Kidney International|May 30, 2020
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetesJingWei Li, Bruce Neal, Vlado Perkovic, et al.
American Heart Journal|March 8, 2017
Cardioversion and subsequent quality of life and natural history of atrial fibrillationSean D Pokorney, Sunghee Kim, Laine Thomas, et al.
Journal of the American Heart Association|May 6, 2016
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) RegistryEmily C O'Brien, Sunghee Kim, Laine Thomas, et al.
American Heart Journal|February 3, 2015
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research ConsortiumJonathan H Seltzer, J Rick Turner, Mary Jane Geiger, et al.
Journal of the American College of Cardiology|February 4, 2022
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to CanagliflozinMuthiah Vaduganathan, Naveed Sattar, Jialin Xu, et al.
American Heart Journal|November 2, 2013
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction studyAkshay Bagai, Paul W Armstrong, Amanda Stebbins, et al.
Endocrinology, Diabetes & Metabolism|July 19, 2021
Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS ProgramKatherine M Wang, JingWei Li, Vivek Bhalla, et al.
Journal of the American Society of Nephrology : JASN|February 5, 2025
Effects of Clazakizumab on Anemia and Iron Metabolism in Patients with Kidney FailureBrendon L Neuen, Benjamin Catanese, Annamarie Chang, et al.
Pageof 64

Showing results (81-90 of 635) with videos related to

Sort By:
Pageof 64
Cardiovascular Diabetology|September 23, 2022
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failureSok Cin Tye, Niels Jongs, Steven G Coca, et al.
Circulation|March 19, 2019
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes MellitusGemma A Figtree, Karin Rådholm, Terrance D Barrett, et al.
Kidney International|May 30, 2020
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetesJingWei Li, Bruce Neal, Vlado Perkovic, et al.
American Heart Journal|March 8, 2017
Cardioversion and subsequent quality of life and natural history of atrial fibrillationSean D Pokorney, Sunghee Kim, Laine Thomas, et al.
Journal of the American Heart Association|May 6, 2016
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) RegistryEmily C O'Brien, Sunghee Kim, Laine Thomas, et al.
American Heart Journal|February 3, 2015
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research ConsortiumJonathan H Seltzer, J Rick Turner, Mary Jane Geiger, et al.
Journal of the American College of Cardiology|February 4, 2022
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to CanagliflozinMuthiah Vaduganathan, Naveed Sattar, Jialin Xu, et al.
American Heart Journal|November 2, 2013
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction studyAkshay Bagai, Paul W Armstrong, Amanda Stebbins, et al.
Endocrinology, Diabetes & Metabolism|July 19, 2021
Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS ProgramKatherine M Wang, JingWei Li, Vivek Bhalla, et al.
Journal of the American Society of Nephrology : JASN|February 5, 2025
Effects of Clazakizumab on Anemia and Iron Metabolism in Patients with Kidney FailureBrendon L Neuen, Benjamin Catanese, Annamarie Chang, et al.
Pageof 64